Global Endothelin Antagonist Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

1 Market Overview

• 1.1 Product Overview and Scope of Endothelin Antagonist Therapy
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Classification of Endothelin Antagonist Therapy by Type
  • 1.3.1 Overview: Global Endothelin Antagonist Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
  • 1.3.2 Global Endothelin Antagonist Therapy Consumption Value Market Share by Type in 2022
  • 1.3.3 Oral
  • 1.3.4 Parenteral
• 1.4 Global Endothelin Antagonist Therapy Market by Application
  • 1.4.1 Overview: Global Endothelin Antagonist Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
  • 1.4.2 Hospitals
  • 1.4.3 Specialty Clinics
  • 1.4.4 Diagnostic Centers
  • 1.4.5 Others
• 1.5 Global Endothelin Antagonist Therapy Market Size & Forecast
• 1.6 Global Endothelin Antagonist Therapy Market Size and Forecast by Region
  • 1.6.1 Global Endothelin Antagonist Therapy Market Size by Region: 2018 VS 2022 VS 2029
  • 1.6.2 Global Endothelin Antagonist Therapy Market Size by Region, (2018-2029)
  • 1.6.3 North America Endothelin Antagonist Therapy Market Size and Prospect (2018-2029)
  • 1.6.4 Europe Endothelin Antagonist Therapy Market Size and Prospect (2018-2029)
  • 1.6.5 Asia-Pacific Endothelin Antagonist Therapy Market Size and Prospect (2018-2029)
  • 1.6.6 South America Endothelin Antagonist Therapy Market Size and Prospect (2018-2029)
  • 1.6.7 Middle East and Africa Endothelin Antagonist Therapy Market Size and Prospect (2018-2029)

2 Company Profiles

• 2.1 Gilead Sciences
  • 2.1.1 Gilead Sciences Details
  • 2.1.2 Gilead Sciences Major Business
  • 2.1.3 Gilead Sciences Endothelin Antagonist Therapy Product and Solutions
  • 2.1.4 Gilead Sciences Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.1.5 Gilead Sciences Recent Developments and Future Plans
• 2.2 Sun Pharmaceutical Industries
  • 2.2.1 Sun Pharmaceutical Industries Details
  • 2.2.2 Sun Pharmaceutical Industries Major Business
  • 2.2.3 Sun Pharmaceutical Industries Endothelin Antagonist Therapy Product and Solutions
  • 2.2.4 Sun Pharmaceutical Industries Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.2.5 Sun Pharmaceutical Industries Recent Developments and Future Plans
• 2.3 Lupin
  • 2.3.1 Lupin Details
  • 2.3.2 Lupin Major Business
  • 2.3.3 Lupin Endothelin Antagonist Therapy Product and Solutions
  • 2.3.4 Lupin Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.3.5 Lupin Recent Developments and Future Plans
• 2.4 Zydus Group
  • 2.4.1 Zydus Group Details
  • 2.4.2 Zydus Group Major Business
  • 2.4.3 Zydus Group Endothelin Antagonist Therapy Product and Solutions
  • 2.4.4 Zydus Group Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.4.5 Zydus Group Recent Developments and Future Plans
• 2.5 Endo International
  • 2.5.1 Endo International Details
  • 2.5.2 Endo International Major Business
  • 2.5.3 Endo International Endothelin Antagonist Therapy Product and Solutions
  • 2.5.4 Endo International Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.5.5 Endo International Recent Developments and Future Plans
• 2.6 Mylan N.V
  • 2.6.1 Mylan N.V Details
  • 2.6.2 Mylan N.V Major Business
  • 2.6.3 Mylan N.V Endothelin Antagonist Therapy Product and Solutions
  • 2.6.4 Mylan N.V Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.6.5 Mylan N.V Recent Developments and Future Plans
• 2.7 Teva Pharmaceutical Industries
  • 2.7.1 Teva Pharmaceutical Industries Details
  • 2.7.2 Teva Pharmaceutical Industries Major Business
  • 2.7.3 Teva Pharmaceutical Industries Endothelin Antagonist Therapy Product and Solutions
  • 2.7.4 Teva Pharmaceutical Industries Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.7.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
• 2.8 Sigmapharm Laboratories
  • 2.8.1 Sigmapharm Laboratories Details
  • 2.8.2 Sigmapharm Laboratories Major Business
  • 2.8.3 Sigmapharm Laboratories Endothelin Antagonist Therapy Product and Solutions
  • 2.8.4 Sigmapharm Laboratories Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.8.5 Sigmapharm Laboratories Recent Developments and Future Plans
• 2.9 Alembic Pharmaceuticals
  • 2.9.1 Alembic Pharmaceuticals Details
  • 2.9.2 Alembic Pharmaceuticals Major Business
  • 2.9.3 Alembic Pharmaceuticals Endothelin Antagonist Therapy Product and Solutions
  • 2.9.4 Alembic Pharmaceuticals Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.9.5 Alembic Pharmaceuticals Recent Developments and Future Plans
• 2.10 Hikma Pharmaceuticals
  • 2.10.1 Hikma Pharmaceuticals Details
  • 2.10.2 Hikma Pharmaceuticals Major Business
  • 2.10.3 Hikma Pharmaceuticals Endothelin Antagonist Therapy Product and Solutions
  • 2.10.4 Hikma Pharmaceuticals Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.10.5 Hikma Pharmaceuticals Recent Developments and Future Plans
• 2.11 Amneal Pharmaceuticals
  • 2.11.1 Amneal Pharmaceuticals Details
  • 2.11.2 Amneal Pharmaceuticals Major Business
  • 2.11.3 Amneal Pharmaceuticals Endothelin Antagonist Therapy Product and Solutions
  • 2.11.4 Amneal Pharmaceuticals Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.11.5 Amneal Pharmaceuticals Recent Developments and Future Plans
• 2.12 AstraZeneca
  • 2.12.1 AstraZeneca Details
  • 2.12.2 AstraZeneca Major Business
  • 2.12.3 AstraZeneca Endothelin Antagonist Therapy Product and Solutions
  • 2.12.4 AstraZeneca Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.12.5 AstraZeneca Recent Developments and Future Plans
• 2.13 Johnsons & Johnsons Private limited
  • 2.13.1 Johnsons & Johnsons Private limited Details
  • 2.13.2 Johnsons & Johnsons Private limited Major Business
  • 2.13.3 Johnsons & Johnsons Private limited Endothelin Antagonist Therapy Product and Solutions
  • 2.13.4 Johnsons & Johnsons Private limited Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
  • 2.13.5 Johnsons & Johnsons Private limited Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global Endothelin Antagonist Therapy Revenue and Share by Players (2018-2023)
• 3.2 Market Share Analysis (2022)
  • 3.2.1 Market Share of Endothelin Antagonist Therapy by Company Revenue
  • 3.2.2 Top 3 Endothelin Antagonist Therapy Players Market Share in 2022
  • 3.2.3 Top 6 Endothelin Antagonist Therapy Players Market Share in 2022
• 3.3 Endothelin Antagonist Therapy Market: Overall Company Footprint Analysis
  • 3.3.1 Endothelin Antagonist Therapy Market: Region Footprint
  • 3.3.2 Endothelin Antagonist Therapy Market: Company Product Type Footprint
  • 3.3.3 Endothelin Antagonist Therapy Market: Company Product Application Footprint
• 3.4 New Market Entrants and Barriers to Market Entry
• 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

• 4.1 Global Endothelin Antagonist Therapy Consumption Value and Market Share by Type (2018-2023)
• 4.2 Global Endothelin Antagonist Therapy Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

• 5.1 Global Endothelin Antagonist Therapy Consumption Value Market Share by Application (2018-2023)
• 5.2 Global Endothelin Antagonist Therapy Market Forecast by Application (2024-2029)

6 North America

• 6.1 North America Endothelin Antagonist Therapy Consumption Value by Type (2018-2029)
• 6.2 North America Endothelin Antagonist Therapy Consumption Value by Application (2018-2029)
• 6.3 North America Endothelin Antagonist Therapy Market Size by Country
  • 6.3.1 North America Endothelin Antagonist Therapy Consumption Value by Country (2018-2029)
  • 6.3.2 United States Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 6.3.3 Canada Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 6.3.4 Mexico Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)

7 Europe

• 7.1 Europe Endothelin Antagonist Therapy Consumption Value by Type (2018-2029)
• 7.2 Europe Endothelin Antagonist Therapy Consumption Value by Application (2018-2029)
• 7.3 Europe Endothelin Antagonist Therapy Market Size by Country
  • 7.3.1 Europe Endothelin Antagonist Therapy Consumption Value by Country (2018-2029)
  • 7.3.2 Germany Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 7.3.3 France Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 7.3.4 United Kingdom Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 7.3.5 Russia Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 7.3.6 Italy Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)

8 Asia-Pacific

• 8.1 Asia-Pacific Endothelin Antagonist Therapy Consumption Value by Type (2018-2029)
• 8.2 Asia-Pacific Endothelin Antagonist Therapy Consumption Value by Application (2018-2029)
• 8.3 Asia-Pacific Endothelin Antagonist Therapy Market Size by Region
  • 8.3.1 Asia-Pacific Endothelin Antagonist Therapy Consumption Value by Region (2018-2029)
  • 8.3.2 China Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 8.3.3 Japan Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 8.3.4 South Korea Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 8.3.5 India Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 8.3.6 Southeast Asia Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 8.3.7 Australia Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)

9 South America

• 9.1 South America Endothelin Antagonist Therapy Consumption Value by Type (2018-2029)
• 9.2 South America Endothelin Antagonist Therapy Consumption Value by Application (2018-2029)
• 9.3 South America Endothelin Antagonist Therapy Market Size by Country
  • 9.3.1 South America Endothelin Antagonist Therapy Consumption Value by Country (2018-2029)
  • 9.3.2 Brazil Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 9.3.3 Argentina Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)

10 Middle East & Africa

• 10.1 Middle East & Africa Endothelin Antagonist Therapy Consumption Value by Type (2018-2029)
• 10.2 Middle East & Africa Endothelin Antagonist Therapy Consumption Value by Application (2018-2029)
• 10.3 Middle East & Africa Endothelin Antagonist Therapy Market Size by Country
  • 10.3.1 Middle East & Africa Endothelin Antagonist Therapy Consumption Value by Country (2018-2029)
  • 10.3.2 Turkey Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 10.3.3 Saudi Arabia Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
  • 10.3.4 UAE Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)

11 Market Dynamics

• 11.1 Endothelin Antagonist Therapy Market Drivers
• 11.2 Endothelin Antagonist Therapy Market Restraints
• 11.3 Endothelin Antagonist Therapy Trends Analysis
• 11.4 Porters Five Forces Analysis
  • 11.4.1 Threat of New Entrants
  • 11.4.2 Bargaining Power of Suppliers
  • 11.4.3 Bargaining Power of Buyers
  • 11.4.4 Threat of Substitutes
  • 11.4.5 Competitive Rivalry
• 11.5 Influence of COVID-19 and Russia-Ukraine War
  • 11.5.1 Influence of COVID-19
  • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

• 12.1 Endothelin Antagonist Therapy Industry Chain
• 12.2 Endothelin Antagonist Therapy Upstream Analysis
• 12.3 Endothelin Antagonist Therapy Midstream Analysis
• 12.4 Endothelin Antagonist Therapy Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Research Process and Data Source